Purdue Signs Two Deals To Diversify Portfolio
Purdue Pharma has made headway this month on its 2016-initiated plans to diversify the company's R&D portfolio away from the pain therapy space, having actioned two collaborative deals with Exicure and AnaBios.
You may also be interested in...
In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.
The private pain specialist is interested in business development opportunities in its core therapeutic space and adjacencies, but also looking at other ‘innovative’ technologies and partnerships with ex-US drug manufacturers, CEO Timney said during an interview.
Mark Timney has been president and CEO of US specialty company Purdue Pharma for just over two years but he's playing a long game to pull the business away from its single-track R&D model towards other opportunities outside pain therapy – its mainstay development area